Literature DB >> 14522370

Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory.

P A Ganz1.   

Abstract

This paper provides a rationale for the importance of studying health outcomes in cancer survivors, including their growing numbers, the need for detailed information on the short and long-term effects of treatment, and the interactions of cancer with other comorbid conditions. However, there are a number of challenges associated with this research. Identification and recruitment of cancer survivors is not always easy, and linking their current health status to details of medical treatment is important, but not always feasible. National surveys and databases are a potential source of information on survivors, but may not provide sufficient details for this type of research. Strategies need to be developed to plan for long-term outcome studies in cancer patients from the very beginning of treatment to obtain the most comprehensive data on the outcomes of survivors.

Entities:  

Mesh:

Year:  2003        PMID: 14522370     DOI: 10.1016/s0959-8049(03)00489-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  24 in total

1.  Impact of oxaliplatin-induced neuropathy: a patient perspective.

Authors:  Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein
Journal:  Support Care Cancer       Date:  2012-03-17       Impact factor: 3.603

Review 2.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

3.  Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism.

Authors:  Kyung Ran Kim; Hyun Cheol Chung; Eun Lee; Se Joo Kim; Kee Namkoong
Journal:  Support Care Cancer       Date:  2011-12-02       Impact factor: 3.603

Review 4.  Cancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches.

Authors:  N Corsini; J Fish; I Ramsey; G Sharplin; I Flight; R Damarell; B Wiggins; C Wilson; D Roder; M Eckert
Journal:  J Cancer Surviv       Date:  2017-04-03       Impact factor: 4.442

5.  Increased health care utilisation among 10-year breast cancer survivors.

Authors:  L V van de Poll-Franse; F Mols; A J J M Vingerhoets; A C Voogd; R M H Roumen; J W W Coebergh
Journal:  Support Care Cancer       Date:  2006-01-10       Impact factor: 3.603

6.  Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry.

Authors:  Floortje Mols; Olga Husson; Jan-Anne Roukema; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2013-05-16       Impact factor: 4.442

7.  Investigating physical symptom burden and personal goal interference in early-stage breast cancer patients.

Authors:  Natalie Stefanic; Peter Caputi; Don C Iverson
Journal:  Support Care Cancer       Date:  2013-11-06       Impact factor: 3.603

8.  Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivors.

Authors:  Neeraj K Arora; Ann S Hamilton; Arnold L Potosky; Julia H Rowland; Noreen M Aziz; Keith M Bellizzi; Carrie N Klabunde; Wendy McLaughlin; Jennifer Stevens
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

Review 9.  Long term physical sequelae after adult-onset cancer.

Authors:  Sophie D Fosså; Rena Vassilopoulou-Sellin; Alv A Dahl
Journal:  J Cancer Surviv       Date:  2007-12-04       Impact factor: 4.442

10.  The impact of disease progression on perceived health status and quality of life of long-term cancer survivors.

Authors:  Melissa S Y Thong; Floortje Mols; Jan-Willem W Coebergh; Jan A Roukema; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2009-06-26       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.